RE: Breakout Finally5 Feb 2021 10:37
FDA Meeting due in Q1 for MRX 0518. Seres got a breakthrough therapy designation for their C-dificil treatment.
This is awarded for a drug that treats a serious or life threatening condition where other available therapies are insufficient.
The oncology update the other day is just more evidence that can hopefully be presented to FDA